Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics
Carregando...
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Citação
BMC UROLOGY, v.17, article ID 113, 8p, 2017
Resumo
Background: Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer in adults. Our aim is to evaluate genes and miRNAs expression profiles involved with angiogenesis and tumor characteristics in ccRCC. Methods: The expression levels of miRNAs miR-99a, 99b, 100; 199a; 106a; 106b; 29a; 29b; 29c; 126; 200a, 200b and their respective target genes: mTOR, HIF1-alpha, VHL, PDGF, VEGF, VEGFR1 and VEGFR2 were analyzed using qRT-PCR in tumor tissue samples from 56 patients with ccRCC. Five samples of benign renal tissue were utilized as control. The expression levels of miRNAs and genes were related to tumor size, Fuhrman nuclear grade and microvascular invasion. Results: miR99a was overexpressed in most samples and its target gene mTOR was underexpressed, this also occurs for miRNAs 106a, 106b, and their target gene VHL. An increase in miR-200b was correlated with high-risk tumors (p = 0.01) while miR-126 overexpression was associated with Fuhrman's low grade (p = 0.03). Conclusions: Our results show that in ccRCC there are changes in miRNAs expression affecting gene expression that could be important in determining the aggressiveness of this lethal neoplasia.
Palavras-chave
Angiogenesis, Genes, microRNAs, Renal cell carcinoma clear cell type
Referências
- Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
- Berghoff AS, 2015, NEUROPATH APPL NEURO, V41, pE41, DOI 10.1111/nan.12185
- Bridge G, 2012, BLOOD, V120, P5063, DOI 10.1182/blood-2012-04-423004
- Bui M H, 2001, Expert Rev Anticancer Ther, V1, P565, DOI 10.1586/14737140.1.4.565
- Bukowski RM, 2009, CANCER, V115, P2273, DOI 10.1002/cncr.24226
- Catto JWF, 2011, EUR UROL, V59, P671, DOI 10.1016/j.eururo.2011.01.044
- Choueiri TK, 2006, SEMIN ONCOL, V33, P596, DOI 10.1053/j.seminoncol.2006.06.003
- Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020
- Cui L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-546
- Dall'Oglio MF, 2007, BJU INT, V100, P552, DOI 10.1111/j.1464-410X.2007.07015.x
- Djordjevic G, 2007, PATHOL RES PRACT, V203, P99, DOI 10.1016/j.prp.2006.12.002
- Ebbinghaus SW, 2004, HEMATOL ONCOL CLIN N, V18, P1143, DOI 10.1016/j.hoc.2004.06.003
- Eklund L, 2013, MOL ONCOL, V7, P259, DOI 10.1016/j.molonc.2013.02.007
- Fendler A, 2011, CLIN CHEM, V57, P954, DOI 10.1373/clinchem.2010.157727
- Grundmann S, 2011, CIRCULATION, V123, P999, DOI 10.1161/CIRCULATIONAHA.110.000323
- Haddad AQ, 2015, CANCER-AM CANCER SOC, V121, P43, DOI 10.1002/cncr.28976
- Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
- Katz B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113700
- Khella HWZ, 2012, TUMOR BIOL, V33, P131, DOI 10.1007/s13277-011-0255-5
- Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
- Ljungberg BJ, 2006, BJU INT, V98, P661, DOI 10.1111/j.1464-410X.2006.06387.x
- Longo R, 2007, ANN ONCOLOGY OFFIC S, V6, pvi141
- Miyamoto H, 2010, PATHOL INT, V60, P1, DOI 10.1111/j.1440-1827.2009.02477.x
- Montironi R, 2000, VIRCHOWS ARCH, V437, P82, DOI 10.1007/s004280000216
- Nikolic I., 2010, J ANGIOGENES RES, V2, P9, DOI 10.1186/2040-2384-2-9
- Posadas EM, 2013, EXPERT OPIN PHARMACO, V14, P2221, DOI 10.1517/14656566.2013.832202
- Roy S, 2012, MICROCIRCULATION, V19, P224, DOI 10.1111/j.1549-8719.2011.00156.x
- Ru YB, 2011, CURR OPIN UROL, V21, P420, DOI 10.1097/MOU.0b013e32834956d6
- Schaefer A, 2010, NAT REV UROL, V7, P286, DOI 10.1038/nrurol.2010.45
- Schaefer A, 2010, UROL ONCOL-SEMIN ORI, V28, P4, DOI 10.1016/j.urolonc.2008.10.021
- Silva-Santos RM, 2013, BRIT J CANCER, V109, P2646, DOI 10.1038/bjc.2013.552
- Slaby O, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-90
- Smaldone MC, 2009, UROL ONCOL-SEMIN ORI, V27, P238, DOI 10.1016/j.urolonc.2007.12.001
- Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270
- van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
- Wang W, 2015, UROL ONCOL, V33, P168
- Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003
- Yuan HX, 2014, TUMOR BIOL, V35, P12757, DOI 10.1007/s13277-014-2602-9
- Zaravinos A, 2012, J UROLOGY, V188, P615, DOI 10.1016/j.juro.2012.03.122
- Zhang CX, 2010, J CARDIOVASC TRANSL, V3, P235, DOI 10.1007/s12265-010-9164-z
- Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080544